» Articles » PMID: 20212084

Mouse Models of the Metabolic Syndrome

Overview
Journal Dis Model Mech
Specialty General Medicine
Date 2010 Mar 10
PMID 20212084
Citations 132
Authors
Affiliations
Soon will be listed here.
Abstract

The metabolic syndrome (MetS) is characterized by obesity concomitant with other metabolic abnormalities such as hypertriglyceridemia, reduced high-density lipoprotein levels, elevated blood pressure and raised fasting glucose levels. The precise definition of MetS, the relationships of its metabolic features, and what initiates it, are debated. However, obesity is on the rise worldwide, and its association with these metabolic symptoms increases the risk for diabetes and cardiovascular disease (among many other diseases). Research needs to determine the mechanisms by which obesity and MetS increase the risk of disease. In light of this growing epidemic, it is imperative to develop animal models of MetS. These models will help determine the pathophysiological basis for MetS and how MetS increases the risk for other diseases. Among the various animal models available to study MetS, mice are the most commonly used for several reasons. First, there are several spontaneously occurring obese mouse strains that have been used for decades and that are very well characterized. Second, high-fat feeding studies require only months to induce MetS. Third, it is relatively easy to study the effects of single genes by developing transgenic or gene knockouts to determine the influence of a gene on MetS. For these reasons, this review will focus on the benefits and caveats of the most common mouse models of MetS. It is our hope that the reader will be able to use this review as a guide for the selection of mouse models for their own studies.

Citing Articles

Controlled induction of type 2 diabetes in mice using high fat diet and osmotic-mini pump infused streptozotocin.

Attrill E, Scharapow O, Perera S, Mayne S, Sumargo N, Ross R Sci Rep. 2025; 15(1):8812.

PMID: 40087321 DOI: 10.1038/s41598-025-89162-2.


Regulation of energy balance by leptin as an adiposity signal and modulator of the reward system.

Asgari R, Caceres-Valdiviezo M, Wu S, Hamel L, Humber B, Agarwal S Mol Metab. 2024; 91():102078.

PMID: 39615837 PMC: 11696864. DOI: 10.1016/j.molmet.2024.102078.


Single Nuclei Transcriptomics Reveals Obesity-Induced Endothelial and Neurovascular Dysfunction: Implications for Cognitive Decline.

Milenkovic D, Nuthikattu S, Norman J, Villablanca A Int J Mol Sci. 2024; 25(20).

PMID: 39456952 PMC: 11508525. DOI: 10.3390/ijms252011169.


Exploring molecular mechanisms of exercise on metabolic syndrome: a bibliometric and visualization study using CiteSpace.

Wan K, Jin Y, Fan R, Xu Q, Li X, Yan H Front Endocrinol (Lausanne). 2024; 15:1408466.

PMID: 39290329 PMC: 11405195. DOI: 10.3389/fendo.2024.1408466.


Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease.

Abdelnabi M, Hassan G, Shoukry N Front Immunol. 2024; 15:1437046.

PMID: 39156888 PMC: 11327067. DOI: 10.3389/fimmu.2024.1437046.


References
1.
Ma K, Cabrero A, Saha P, Kojima H, Li L, Chang B . Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem. 2002; 277(38):34658-61. DOI: 10.1074/jbc.C200362200. View

2.
Marti A, Corbalan M, Forga L, Martinez J, Hinney A, Hebebrand J . A novel nonsense mutation in the melanocortin-4 receptor associated with obesity in a Spanish population. Int J Obes Relat Metab Disord. 2003; 27(3):385-8. DOI: 10.1038/sj.ijo.0802244. View

3.
Farooqi I, Keogh J, Yeo G, Lank E, Cheetham T, ORahilly S . Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003; 348(12):1085-95. DOI: 10.1056/NEJMoa022050. View

4.
Mertens A, Verhamme P, Bielicki J, Phillips M, Quarck R, Verreth W . Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation. 2003; 107(12):1640-6. DOI: 10.1161/01.CIR.0000056523.08033.9F. View

5.
Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H . Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003; 42(3):231-4. DOI: 10.1161/01.HYP.0000083488.67550.B8. View